Shantanu Narayen - PFIZER DRN Director

PFIZ34
  

BRL 58.94  1.33  2.31%   

  Director
Mr. Shantanu Narayen is an Independent Director of Pfizer Inc., since September 27, 2013. Mr. Narayen is President and Chief Executive Officer and Director of Adobe Systems Incorporated, a producer of creative and digital marketing software. Prior to his appointment as CEO in December 2007, held various leadership roles at Adobe, including President and Chief Operating Officer, Executive Vice President of Worldwide Products, and Senior Vice President of Worldwide Product Development. Director of Dell Inc. from 2009 until October 2013 and Director of Metavante Technologies Inc. from 2007 until 2009. President of the Board of Adobe Foundation, which funds philanthropic initiatives around the world
Age: 54  Director Since 2013      
212 733 2323  https://www.pfizer.com
Narayen’s experience as Chairman, President and CEO of Adobe brings strong leadership and management skills to the Board, and his past roles in worldwide product development provide valuable global operations experience. He also serves as a member and Vice Chairman of USIndia Strategic Partnership Forum. His experiences as a director on other public boards provides a broad perspective on issues facing public companies and governance matters. Pfizer benefits from Mr. Narayen’s extensive knowledge in technology, product innovation and leadership in the digital marketing category through his experience in the technology industry. In addition, his deep knowledge and understanding of business risks through his leadership at a global technology company provide further insight and perspective to the Board.

Shantanu Narayen Latest Insider Activity

Tracking and analyzing the buying and selling activities of Shantanu Narayen against PFIZER DRN stock is an integral part of due diligence when investing in PFIZER DRN. Shantanu Narayen insider activity provides valuable insight into whether PFIZER DRN is net buyers or sellers over its current business cycle. Note, PFIZER DRN insiders must abide by specific rules, including filing SEC forms every time they buy or sell PFIZER DRN'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

PFIZER DRN Management Efficiency

PFIZER DRN has return on total asset (ROA) of 10.0 % which means that it generated profit of $10.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 31.87 %, meaning that it generated $31.87 on every $100 dollars invested by stockholders. PFIZER DRN management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 36.44 B in total debt with debt to equity ratio (D/E) of 0.44, which is about average as compared to similar companies. PFIZER DRN has a current ratio of 1.37, which is within standard range for the sector. Debt can assist PFIZER DRN until it has trouble settling it off, either with new capital or with free cash flow. So, PFIZER DRN's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PFIZER DRN sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PFIZER to invest in growth at high rates of return. When we think about PFIZER DRN's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Rebecca HendersonAMGEN DRN
2009
David BaltimoreAMGEN DRN
1999
Robert WilliamsAMGEN DRN
2014
Vance CoffmanAMGEN DRN
2013
Bruno MachadoDIMED ON N2
N/A
Claudio ElyDIMED ON N2
N/A
Francois CarbonnelAMGEN DRN
2008
Brian DrukerAMGEN DRN
2018
Charles HolleyAMGEN DRN
2017
Ronald SugarAMGEN DRN
2010
Sergio PizzatoDIMED ON N2
N/A
Tyler JacksAMGEN DRN
2012
Judith PelhamAMGEN DRN
1995
Sanders WilliamsAMGEN DRN
2014
Fred HassanAMGEN DRN
2015
Wanda AustinAMGEN DRN
2017
Frank BiondiAMGEN DRN
2002
Gregory GarlandAMGEN DRN
2013
Marcel SapirDIMED ON N2
2010
Antonio NappDIMED ON N2
N/A
Ellen KullmanAMGEN DRN
2017
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. PFIZER DRN operates under Drug ManufacturersGeneral classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 79000 people. PFIZER DRN (PFIZ34) is traded on Sao Paolo Stock Exchange in Brazil and employs 79,000 people.

PFIZER DRN Leadership Team

Elected by the shareholders, the PFIZER DRN's board of directors comprises two types of representatives: PFIZER DRN inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PFIZER. The board's role is to monitor PFIZER DRN's management team and ensure that shareholders' interests are well served. PFIZER DRN's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PFIZER DRN's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Young, Group President of Global Established Pharma Bus.
Frank DAmelio, CFO and Executive VP of Bus. Operations
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Director
James Smith, Director
Dennis Ausiello, Independent Director
Mikael Dolsten, President - Worldwide Research and Development
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President CTO and Digital Officer
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
Alexander Mackenzie, Executive Vice President Chief Development Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Executive Vice President - Corporate Affairs
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Executive Vice President Chief Compliance and Risk Officer
Dan Littman, Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President - Pfizer Essential Health
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

PFIZER Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PFIZER DRN a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PFIZER DRN in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PFIZER DRN's short interest history, or implied volatility extrapolated from PFIZER DRN options trading.

Currently Active Assets on Macroaxis

Please check Your Equity Center. Note that the PFIZER DRN information on this page should be used as a complementary analysis to other PFIZER DRN's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Tools for PFIZER Stock

When running PFIZER DRN price analysis, check to measure PFIZER DRN's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PFIZER DRN is operating at the current time. Most of PFIZER DRN's value examination focuses on studying past and present price action to predict the probability of PFIZER DRN's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move PFIZER DRN's price. Additionally, you may evaluate how the addition of PFIZER DRN to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go